In adult rats, 2 weeks of chronic subcutaneous IGF2 administration, whether with daily injections or constant infusion from an implanted osmotic mini‐pump, does not affect body composition or metabolic measures168, 169; 30 days of subcutaneous IGF2 reduced markers of oxidative stress in the hippocampus and cortex of aged rats128; oxidative stress is a common feature of AD pathology.170. This evidence concerns the gene IGF2 and Alzheimer disease.